Charde Vivek, Sanklecha Mukesh, Rajan Priyank, Naeem Babar, Wanjari Mayur, Mittal Gaurav, Adrien Tanjmi Djabo Eric
Department of Pediatrics, Bombay Hospital Institute of Medical Sciences, Mumbai, India.
Department of Pediatrics, Jinnah Hospital, Lahore, Pakistan.
J Family Med Prim Care. 2025 Feb;14(2):680-686. doi: 10.4103/jfmpc.jfmpc_348_24. Epub 2025 Feb 21.
Pain and fever are common paediatric complaints that demand meticulous symptom alleviation to ensure the child's holistic well-being. Paracetamol, ibuprofen, and their synergistic coadministration occupy a crucial position, rendering the management of these symptoms efficacious. This study aims to evaluate the safety and adverse effects of paracetamol, ibuprofen, and their combination comprehensively.
A prospective observational study was conducted at the Department of Paediatrics, Bombay Hospital Institute of Medical Sciences, Mumbai, India. 108 paediatric patients aged 6 months to 18 years experiencing fever, pain, or both. Patients were assigned to receive one of the three medications and were randomized into one of the three groups: paracetamol, ibuprofen, or a combination. Baseline and 48-hour assessments included vital signs, adverse effects, and biochemical markers including SGOT, SGPT, serum creatinine, platelet count, and occult blood in stool samples.
Paracetamol, ibuprofen, and their combination were found to be equally effective in relieving symptoms associated with fever and pain. The most common adverse effect observed was vomiting, with minimal occurrences of rash, cough, and diarrhoea. Biochemical markers, including SGOT, SGPT, serum creatinine, platelet count, and occult blood in stool samples, remained within normal ranges after 48 h of drug administration.
This study affirms the safety of paracetamol, ibuprofen, and their combination for paediatric pain and fever management. Minimal adverse effects and the absence of significant biochemical derangements support their favourable risk-benefit profiles, emphasizing their importance in paediatric clinical practice.
疼痛和发热是常见的儿科病症，需要精心缓解症状以确保儿童的整体健康。对乙酰氨基酚、布洛芬及其联合使用在这些症状的管理中占据关键地位，使症状管理有效。本研究旨在全面评估对乙酰氨基酚、布洛芬及其组合的安全性和不良反应。
在印度孟买医院医学科学研究所儿科学部进行了一项前瞻性观察研究。108名年龄在6个月至18岁之间的儿科患者出现发热、疼痛或两者皆有。患者被分配接受三种药物之一，并随机分为三组之一：对乙酰氨基酚、布洛芬或联合用药组。基线和48小时评估包括生命体征、不良反应以及生化指标，包括谷草转氨酶、谷丙转氨酶、血清肌酐、血小板计数和粪便样本中的潜血。
发现对乙酰氨基酚、布洛芬及其组合在缓解与发热和疼痛相关的症状方面同样有效。观察到的最常见不良反应是呕吐，皮疹、咳嗽和腹泻的发生率极低。给药48小时后，包括谷草转氨酶、谷丙转氨酶、血清肌酐、血小板计数和粪便样本中的潜血在内的生化指标仍在正常范围内。
本研究证实了对乙酰氨基酚、布洛芬及其组合用于儿科疼痛和发热管理的安全性。不良反应轻微且无明显生化紊乱支持其良好的风险效益比，强调了它们在儿科临床实践中的重要性。
